You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

364 Results
Drug
Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Drug
Other Name(s): Iclusig®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Dec 2025
Drug
Other Name(s): Afinitor®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Dec 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
ODB - General Benefit
    exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus,
exemestane
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Lung, 
Neuroendocrine (Lung)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib (Unfunded),
everolimus
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Guidelines and Advice
Status: Current
ID: GL1-10
Version: 4
Mar 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
vinBLAStine,
dacarbazine,
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025

Pages